Omada Health was founded in 2011 by Adrian James, Andrew Di Michele, and Sean Duffy. CEO Duffy told Bloomberg in 2022 that while he intends to eventually take the company public, he "plans to stay independent for now...Especially given the current state of the public markets." Duffy added that "I tell the company that our job here is to make sure that when we make that flip to public it doesn’t feel like we’re doing anything differently." These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Omada Health is a digital health firm that uses virtual consultations and monitoring devices to provide remote care for patients who suffer from chronic illness. In 2020 the company acquired Physera, a telehealth provider that specializes in musculoskeletal care. Omada Health has raised more than $440 million in venture capital funding from investors including Fidelity Management & Research Company, aMoon, Perceptive Advisors, Wellington Management, and Civilization Ventures. A $192 million Series E funding round brought the company's post-money valuation to more than $1 billion.
| Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
|---|---|---|---|---|---|---|
| 02/23/2022 | Series E | $192MM | $xx.xx | $1.02B | Amoon, Civilization Ventures, Fidelity, Perceptive Advisors, Wellington Management | |
|
Price per Share
$xx.xx
Shares Outstanding
32,025,620
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amoon, Civilization Ventures, Fidelity, Perceptive Advisors, Wellington Management
|
||||||
| 03/16/2021 | Series D-1 | $27MM | $xx.xx | $780.77MM | Undisclosed Investors | |
|
Price per Share
$xx.xx
Shares Outstanding
4,503,601
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
| 05/19/2020 | Series D | $112.47MM | $xx.xx | $612.85MM | Andreessen Horowitz, Cigna Ventures, Civilization Ventures, Kaiser Permanente Ventures, Norwest Venture Partners, Perceptive Advisors, Providence Ventures, Sanofi-Genzyme Bioventures, Us Venture Partners, Wellington Management | |
|
Price per Share
$xx.xx
Shares Outstanding
22,330,212
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Cigna Ventures, Civilization Ventures, Kaiser Permanente Ventures, Norwest Venture Partners, Perceptive Advisors, Providence Ventures, Sanofi-Genzyme Bioventures, Us Venture Partners, Wellington Management
|
||||||
| 05/10/2017 | Series C-1 | $49.99MM | $xx.xx | $320.25MM | Andreessen Horowitz, Cigna, Civilization Ventures, Drx Capital, Ge Ventures, Humana, Kaiser Permanente Ventures, Norwest Venture Partners, Providence Ventures, Sanofi Genzyme Bioventures, U.S. Venture Partners | |
|
Price per Share
$xx.xx
Shares Outstanding
13,357,797
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Cigna, Civilization Ventures, Drx Capital, Ge Ventures, Humana, Kaiser Permanente Ventures, Norwest Venture Partners, Providence Ventures, Sanofi Genzyme Bioventures, U.S. Venture Partners
|
||||||
| 10/01/2015 | Series C | $48.67MM | $xx.xx | $216.43MM | Andreessen Horowitz, Designer Fund, Drx Capital, Ge Ventures, Humana Ventures, Ideo Futures, Norwest Venture Partners, Providence Ventures, Rock Health, Us Venture Partners | |
|
Price per Share
$xx.xx
Shares Outstanding
15,385,707
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Designer Fund, Drx Capital, Ge Ventures, Humana Ventures, Ideo Futures, Norwest Venture Partners, Providence Ventures, Rock Health, Us Venture Partners
|
||||||
| 04/09/2014 | Series B | $23.33MM | $xx.xx | $60.57MM | Andreessen Horowitz, Kaiser Permanente Ventures, The Vertical Group, U.S. Venture Partners | |
|
Price per Share
$xx.xx
Shares Outstanding
19,724,378
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Kaiser Permanente Ventures, The Vertical Group, U.S. Venture Partners
|
||||||
| 03/21/2013 | Series A | $6.43MM | $xx.xx | $16.11MM | Founder Collective, Healthtech Capital, Kapor Capital, New Enterprise Associates, The Vertical Group, Triplepoint Capital, U.S. Venture Partners | |
|
Price per Share
$xx.xx
Shares Outstanding
12,027,426
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Founder Collective, Healthtech Capital, Kapor Capital, New Enterprise Associates, The Vertical Group, Triplepoint Capital, U.S. Venture Partners
|
||||||
The majority of Americans live with chronic conditions — like diabetes and arthritis — and 90% of healthcare spending in the U.S. goes toward chronic and mental health conditions, according to data sourced by the CDC.
| Last Funding Round | ||||||||
|---|---|---|---|---|---|---|---|---|
| Company | Forge Price | Forge Price Change 5 | Last Closed Trade | Share Class | Post-Money Valuation | Price per Share | Amount Raised | |
 | Anduril | $42.52 | +42.78% | $xx.xx | Series G | $28B | $xx.xx | $2.58B |
 | Cerebras | $28.78 | -0.14% | $xx.xx | Series F-1 | $2.87B | $xx.xx | $420MM |
 | Discord | $239.72 | +6.61% | $xx.xx | Series I | $15.2B | $xx.xx | $500MM |
 | Klarna | $37.31 | +21.02% | $xx.xx | Unknown | -- | -- | -- |
 | Kraken | $22.43 | +0.4% | $xx.xx | Series B | $5.52B | $xx.xx | $52.5MM |
 | Figure | $5.76 | +7.87% | $xx.xx | Series D | $3.33B | $xx.xx | $220MM |
 | Liquid Death | $9.00 | -6.25% | $xx.xx | Series F-1 | $1.4B | $xx.xx | $67.61MM |
 | Figma | $38.00 | +0.03% | $xx.xx | Series E | $10B | $xx.xx | $200MM |
 | Circle | $30.00 | +17.65% | $xx.xx | Series F | $8.05B | $xx.xx | $401MM |
 | Chime | $31.50 | +0.8% | $xx.xx | Series G | $24.93B | $xx.xx | $1.1B |
Updated on: May 2, 2025
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.